Iodixanol
Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media
Sold as VISIPAQUE 270 · VISIPAQUE 320
- Drug class
- Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media
- Availability
- Prescription only
- Routes
- Intravascular, Intra-Arterial, Intravenous
- Markets covered
- 3
- Products on record
- 7
- FDA reports (12 mo)
- 239
Overview
Iodixanol is an active pharmaceutical ingredient in the Watersoluble, Nephrotropic, Low Osmolar X-Ray Contrast Media group (V08AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | February 20, 2026 |
| US United States | FDA | 1 | July 21, 2023 |
| CA Canada | Health Canada | 4 | June 13, 2025 |
GBUnited Kingdom· MHRA
2 products
Uses
This medicinal product is for diagnostic use only. DSA), urography, venography, CT-enhancement. Lumbar, thoracic and cervical myelography. Arthrography, hysterosalpingography (HSG) and studies of the gastrointestinal tract. In children it is used for cardioangiography, urography, CT- enhancement and studies of the upper gastrointestinal tract.
How to take
USUnited States· FDA
1 product
Uses
1 ) Adults and pediatric patients 12 years of age and over Intra-arterial digital subtraction angiography (270 mg Iodine/mL and 320 mg Iodine/mL). Angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography (320 mg Iodine/mL).
Pediatric patients less than 12 years of age Angiocardiography, cerebral arteriography, and visceral arteriography (320 mg Iodine/mL). 2 ) Adults and pediatric patients 12 years of age and over Computed tomography (CT) imaging head and body (270 mg Iodine/mL and 320 mg Iodine/mL).
Excretory urography (270 mg Iodine/mL and 320 mg Iodine/mL). Peripheral venography (270 mg Iodine/mL). Coronary computed tomography angiography (CCTA) to assist diagnostic evaluation of patients with suspected coronary artery disease (320 mg Iodine/mL).
Pediatric patients less than 12 years of age CT imaging of the head and body (270 mg Iodine/mL). Excretory urography (270 mg Iodine/mL). 1 Intra-arterial Procedures Adult and pediatric patients 12 years of age and older (270 mg Iodine/mL and 320 mg Iodine/mL) intra-arterial digital subtraction angiography (IA-DSA).
CACanada· Health Canada
4 products
4 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Brands in Canada (2)
Drug interactions
Known interactions involving Iodixanol. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL006370018 · revised February 20, 2026
- [2]FDA DailyMed · 0fe89ea2-04f7-46… · revised July 21, 2023 [PDF]
- [3]Health Canada (DPD) · 02145766 · revised March 22, 2025
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.